In a real-world, propensity score–matched cohort study of 10,997 adults per group with chronic migraine, initiation of a glucagon-like peptide-1 receptor agonist (GLP-1RA) was associated with lower risks of emergency department visits, hospitalizations, nerve block procedures, and triptan use over 12 months compared with topiramate. GLP-1RA use was also linked to reduced escalation to additional preventive therapies—including tricyclic antidepressants, valproate, gepants, calcitonin gene-related peptide monoclonal antibodies, and serotonin-norepinephrine reuptake inhibitors—suggesting a potential adjunctive role in migraine management that warrants prospective evaluation.

Source: American Academy of Neurology Abstract, Press Release